Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24/7 phone-based referral.

Source: PubMed, NCBI / U.S. National Library of Medicine

British journal of haematologyInfante Joana Brioso, Aguiar Eliana, Sá Inês, et al.Published 6/8/2026Last synced 6/10/2026Status: syncedPMID: 42259659DOI: 10.1111/bjh.70608

A 24/7 phone-based referral system allows for the fast transfer of acute promyelocytic leukaemia (APL) patients to select sites specialized in APL in Portugal. A reduction in the early death (ED) rate from 11.4% in non-high-risk patients to 3.7% in this cohort and universal complete response (CR) plus measurable residual disease (MRD) negativity were achieved with frontline arsenic trioxide (ATO) in APL.

Educational only

This information is for general education and is not medical advice. Always talk to a licensed U.S. clinician about your situation, medications, or treatment decisions.